Accuray (ARAY) 10-Q 3 Nov 22 2023 Q1 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	3 Months Ended
	Sep. 30, 2022	Oct. 28, 2022
Cover [Abstract]
Entity Registrant Name	ACCURAY INCORPORATED
Entity Central Index Key	0001138723
Document Type	10-Q
Document Period End Date	Sep. 30, 2022
Amendment Flag	false
Current Fiscal Year End Date	--06-30
Entity Current Reporting Status	Yes
Trading Symbol	ARAY
Entity Filer Category	Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		93,778,769
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	Q1
Entity File Number	001-33301
Entity Tax Identification Number	20-8370041
Entity Address, Address Line One	1310 Chesapeake Terrace
Entity Address, City or Town	Sunnyvale
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	94089
City Area Code	408
Local Phone Number	716-4600
Entity Incorporation, State or Country Code	DE
Entity Interactive Data Current	Yes
Document Quarterly Report	true
Document Transition Report	false
Title of 12(b) Security	Common Stock, $0.001 par value per share
Security Exchange Name	NASDAQ

Unaudited Condensed Consolidate

Unaudited Condensed Consolidated Balance Sheets - USD ($) $ in Thousands		Sep. 30, 2022	Jun. 30, 2022
Current assets:
Cash and cash equivalents		$ 81,007	$ 88,737
Restricted cash		203	204
Accounts receivable, net of allowance for credit losses of $848 and $1,000 as of September 30, 2022 and June 30, 2022, respectively (a)	[1]	77,029	94,442
Inventories		152,624	142,254
Prepaid expenses and other current assets (b)	[2]	24,241	23,794
Deferred cost of revenue		161	1,459
Total current assets		335,265	350,890
Property and equipment, net		10,938	12,685
Investment in joint venture		12,776	13,879
Operating lease right-of-use assets, net		26,789	16,798
Goodwill		57,658	57,840
Intangible assets, net		214	250
Long-term restricted cash		1,180	1,213
Other assets		21,529	19,294
Total assets		466,349	472,849
Current liabilities:
Accounts payable		32,945	31,337
Accrued compensation		30,890	29,441
Operating lease liabilities, current		4,864	8,567
Other accrued liabilities		30,201	30,285
Customer advances		17,983	25,290
Deferred revenue		69,948	75,375
Short-term debt		5,705	8,563
Total current liabilities		192,536	208,858
Long-term liabilities:
Operating lease liabilities, non-current		24,123	10,453
Long-term other liabilities		3,626	3,748
Deferred revenue, non-current		28,453	24,694
Long-term debt		170,620	171,907
Total liabilities		419,358	419,660
Commitments and contingencies (Note 9)
Stockholders' equity:
Common stock, $0.001 par value; authorized: 200,000,000 shares as of September 30, 2022 and June 30, 2022, respectively; issued and outstanding: 93,778,769 and 93,499,500 shares at September 30, 2022 and June 30, 2022, respectively		94	94
Additional paid-in-capital		546,117	543,211
Accumulated other comprehensive income (loss)		(1,249)	2,406
Accumulated deficit		(497,971)	(492,522)
Total stockholders' equity		46,991	53,189
Total liabilities and stockholders' equity		$ 466,349	$ 472,849
[1] Includes trade receivable from the China joint venture, an equity method invest ment of $ 18,591 and $ 24,828 at September 30, 2022 and June 30, 2022 , respectively. See Note 14. Includes other receivable from the China joint venture, an equity method investment of $ 779 and $ 861 at September 30, 2022 and June 30, 2022 , respectively.

Unaudited Condensed Consolida_2

Unaudited Condensed Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Sep. 30, 2022	Jun. 30, 2022
Accounts receivable, allowance for credit losses (in dollars)	$ 848	$ 1,000
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, authorized shares	200,000,000	200,000,000
Common stock, issued shares	93,778,769	93,499,500
Common stock, outstanding shares	93,778,769	93,499,500
Accounts receivable from joint venture	$ 18,591	$ 24,828
Prepaid Expenses and Other Current Assets
Accounts receivable from joint venture	$ 779	$ 861

Unaudited Condensed Consolida_3

Unaudited Condensed Consolidated Statements of Operations and Comprehensive Income - USD ($) shares in Thousands, $ in Thousands		3 Months Ended
		Sep. 30, 2022	Sep. 30, 2021
Net revenue:
Total net revenue		$ 96,493	$ 107,442
Cost of revenue:
Total cost of revenue	[1]	61,896	67,918
Gross profit		34,597	39,524
Operating expenses:
Research and development	[2]	14,092	14,382
Selling and marketing		10,795	11,271
General and administrative		11,892	11,460
Total operating expenses		36,779	37,113
Income (loss) from operations		(2,182)	2,411
Loss on equity method investment, net		(368)	(340)
Other expense, net		(2,558)	(2,668)
Loss before provision for income taxes		(5,108)	(597)
Provision for income taxes		341	431
Net loss		$ (5,449)	$ (1,028)
Net loss per share - basic		$ (0.06)	$ (0.01)
Net loss per share - diluted		$ (0.06)	$ (0.01)
Weighted average common shares used in computing net loss per share:
Basic		93,529	90,838
Diluted		93,529	90,838
Net loss		$ (5,449)	$ (1,028)
Foreign currency translation adjustment		(3,655)	231
Comprehensive loss		(9,104)	(797)
Products
Net revenue:
Total net revenue	[3]	44,623	52,759
Cost of revenue:
Total cost of revenue		28,850	31,509
Services
Net revenue:
Total net revenue	[4]	51,870	54,683
Cost of revenue:
Total cost of revenue		$ 33,046	$ 36,409
[1] Includes cost of revenue from sales to the China joint venture, an equity method investment, of $ 5,907 and $ 8,044 during the three months ended September 30, 2022 and September 30, 2021, respectively . Includes chargeback to the China joint venture, an equity method investment, related to a research and development project of $ 779 and $ 579 during the three months ended September 30, 2022 and September 30, 2021, respectively . Includes sales to the China joint venture, an equity method investment, of $ 8,869 and $ 5,920 during the three months ended September 30, 2022 and September 30, 2021, respectively. See Note 14. Includes sales to the China joint venture, an equity method investment, of $ 2,957 and $ 3,638 during the three months ended September 30, 2022 and September 30, 2021, respectively. See Note 14.

Unaudited Condensed Consolida_4

Unaudited Condensed Consolidated Statements of Operations and Comprehensive Income (Parenthetical) - USD ($) $ in Thousands		3 Months Ended
		Sep. 30, 2022	Sep. 30, 2021
Total net revenue		$ 96,493	$ 107,442
Total cost of revenue	[1]	61,896	67,918
Research and development	[2]	14,092	14,382
Products
Total net revenue	[3]	44,623	52,759
Total cost of revenue		28,850	31,509
Services
Total net revenue	[4]	51,870	54,683
Total cost of revenue		33,046	36,409
Revenue from Joint Venture
Total cost of revenue		5,907	8,044
Research and development		779	579
Revenue from Joint Venture | Products
Total net revenue		8,869	5,920
Revenue from Joint Venture | Services
Total net revenue		$ 2,957	$ 3,638
[1] Includes cost of revenue from sales to the China joint venture, an equity method investment, of $ 5,907 and $ 8,044 during the three months ended September 30, 2022 and September 30, 2021, respectively . Includes chargeback to the China joint venture, an equity method investment, related to a research and development project of $ 779 and $ 579 during the three months ended September 30, 2022 and September 30, 2021, respectively . Includes sales to the China joint venture, an equity method investment, of $ 8,869 and $ 5,920 during the three months ended September 30, 2022 and September 30, 2021, respectively. See Note 14. Includes sales to the China joint venture, an equity method investment, of $ 2,957 and $ 3,638 during the three months ended September 30, 2022 and September 30, 2021, respectively. See Note 14.

Unaudited Condensed Consolida_5

Unaudited Condensed Consolidated Statements of Stockholders' Equity - USD ($) $ in Thousands	Total	Cumulative adjustment due to adoption of ASU No. 2020-06	Common Stock	Additional Paid-in Capital	Additional Paid-in Capital Cumulative adjustment due to adoption of ASU No. 2020-06	Accumulated Other Comprehensive Income / (Loss)	Accumulated Deficit	Accumulated Deficit Cumulative adjustment due to adoption of ASU No. 2020-06
Balance at Jun. 30, 2021	$ 68,840	$ (24,784)	$ 91	$ 554,680	$ (25,633)	$ 2,093	$ (488,024)	$ 849
Balance (in shares) at Jun. 30, 2021			90,822
Issuance of restricted stock (in shares)			97
Share-based compensation	2,506			2,506
Net loss	(1,028)						(1,028)
Foreign currency translation adjustment	231					231
Balance at Sep. 30, 2021	45,765		$ 91	531,553		2,324	(488,203)
Balance (in shares) at Sep. 30, 2021			90,919
Balance at Jun. 30, 2022	$ 53,189		$ 94	543,211		2,406	(492,522)
Balance (in shares) at Jun. 30, 2022	93,499,500		93,500
Issuance of restricted stock (in shares)			279
Share-based compensation	$ 2,906			2,906		0
Share-based compensation (in shares)			0
Net loss	(5,449)						(5,449)
Foreign currency translation adjustment	(3,655)					(3,655)
Balance at Sep. 30, 2022	$ 46,991		$ 94	$ 546,117		$ (1,249)	$ (497,971)
Balance (in shares) at Sep. 30, 2022	93,778,769		93,779

Unaudited Condensed Consolida_6

Unaudited Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	3 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Cash flows from operating activities
Net loss	$ (5,449)	$ (1,028)
Adjustments to reconcile net loss to net cash provided by operating activities:
Depreciation and amortization	1,176	1,419
Share-based compensation	2,916	2,516
Amortization of debt issuance costs	219	156
Provision (reversal of provision) for credit losses	(23)	303
Provision for write-down of inventories	769	1,007
Loss on disposal of property and equipment	2	22
Loss on equity method investment	368	340
Deferral of equity method investment intra-entity profit margin from sales	39	1,738
Changes in assets and liabilities:
Accounts receivable	15,466	(9,178)
Inventories	(12,355)	(2,093)
Prepaid expenses and other assets	(2,183)	(1,487)
Deferred cost of revenue	1,298	516
Accounts payable	2,371	3,575
Operating lease liabilities, net of operating lease right-of-use assets	(25)	(217)
Accrued liabilities	1,851	(2,302)
Customer advances	(6,874)	(1,935)
Deferred revenues	480	(1,952)
Net cash provided by (used in) operating activities	46	(8,600)
Cash flows from investing activities
Purchases of property and equipment	(1,272)	(1,456)
Net cash used in investing activities	(1,272)	(1,456)
Cash flows from financing activities
Paydown under Term Loan Facility	(1,500)	(1,000)
Repayments under the Notes	(2,865)	0
Net cash used in financing activities	(4,365)	(1,000)
Effect of exchange rate changes on cash, cash equivalents and restricted cash	(2,173)	(654)
Net decrease in cash, cash equivalents and restricted cash	(7,764)	(11,710)
Cash, cash equivalents and restricted cash at beginning of period	90,154	118,201
Cash, cash equivalents and restricted cash at end of period	82,390	106,491
Supplemental disclosures of cash flow information:
Reclassification of equity component of convertible notes into liabilities upon adoption of ASU 2020-06	$ 0	$ 25,633

The Company and its Significant

The Company and its Significant Accounting Policies	3 Months Ended
	Sep. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
The Company and its Significant Accounting Policies	Note 1. The Company and its Significant Accounting Policies The Company Accuray Incorporated (together with its subsidiaries, the “Company” or “Accuray”) designs, develops and sells advanced radiosurgery and radiation therapy systems for the treatment of tumors throughout the body. The Company is incorporated in Delaware and has its principal place of business in Sunnyvale, California. The Company has primary offices in the United States, Switzerland, China, Hong Kong and Japan and conducts its business worldwide. Basis of Presentation The unaudited condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All significant inter-company transactions and balances have been eliminated in consolidation. The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with United States generally accepted accounting principles (“GAAP”), pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”). Certain information and note disclosures have been condensed or omitted pursuant to such rules and regulations. The unaudited condensed consolidated financial statements have been prepared on the same basis as the annual financial statements and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary for a fair presentation of the periods presented. The results for the three months ended September 30, 2022, are not necessarily indicative of the results to be expected for the fiscal year ending June 30, 2023, or for any other future interim period or fiscal year. These unaudited condensed consolidated financial statements should be read in conjunction with the Company’s audited consolidated financial statements and accompanying notes for the fiscal year ended June 30, 2022 included in the Company’s Annual Report on Form 10-K filed with the SEC on August 17, 2022. Risks and Uncertainties The ongoing COVID-19 pandemic has created significant global economic uncertainty, adversely impacted the business of the Company's customers, partners and vendors, contributed to supply chain and labor issues, and has impacted its business and results of operations in the past and could further impact its results of operations and cash flows in the future. The Company is also subject to risks and uncertainties caused by events with significant macroeconomic impacts, including, but not limited to, the Russian invasion of Ukraine, inflation, actions taken to counter inflation and foreign currency exchange rate fluctuations. These conditions have created and may continue to create significant disruptions with respect to demand for the Company's products and services; the operating procedures and workflow of its customers, particularly hospitals; its ability to continue to manufacture its products; and the reliability of its supply chain, which have impacted and could continue to impact its revenue, expenses and operating results. Use of Estimates The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, expenses, and related disclosures at the date of the financial statements. The Company assessed certain accounting matters that generally require consideration of forecasted financial information in context with the information reasonably available to the Company. Key estimates and assumptions made by the Company relate to revenue recognition and the assessment of stand-alone selling price, assessment of recoverability of goodwill, valuation of our equity method investment CNNC Accuray (Tianjin) Medical Technology Co. Ltd., the Company’s joint venture in China (the “JV”) , valuation of inventories, annual performance related bonuses, allowance for credit losses and loss contingencies. Actual results could differ materially from those estimates. Significant Accounting Policies There have been no changes in the Company’s significant accounting policies during the three months ended September 30, 2022, compared to the significant accounting policies described in its Annual Report on Form 10-K for the fiscal year ended June 30, 2022 .

Recent Accounting Pronouncement

Recent Accounting Pronouncements	3 Months Ended
	Sep. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Recent Accounting Pronouncements	Note 2. Recent Accounting Pronouncements Accounting Pronouncement Not Yet Effective In March 2020, the FASB issued an update (ASU 2020-04) establishing Accounting Standards Codification (“ASC”) Topic 848, Reference Rate Reform. ASU 2020-04 contains practical expedients for reference rate reform related activities that impact debt, leases, derivatives and other contracts. The guidance in ASU 2020-04 is optional and may be elected over time as reference rate reform activities occur. The Company’s Term Loan Facility and Revolving Credit Facility applies Eurodollar rate LIBOR to the variable component of the interest rate, or if a Benchmark transition event, or an early opt-in election, as applicable occurred a transition to the use of the Secured Overnight Financing Rate ("SOFR") to replace such rate. This accounting standard update was effective upon issuance and may be applied prospectively through December 31, 2022. In October 2022, the Company will begin to use the SOFR to calculate the variable component of the interest rate for its Term Loan Facility and Revolving Credit Facility. The change to SOFR will not have a material impact on the Company's financial statements.

Revenue

Revenue	3 Months Ended
	Sep. 30, 2022
Revenue from Contract with Customer [Abstract]
Revenue	Note 3. Revenue Contract Balances The timing of revenue recognition, billings, and cash collections results in trade receivables, unbilled receivables, and deferred revenues on the unaudited condensed consolidated balance sheets. The Company may offer longer or extended payments of more than one year for qualified customers in some circumstances. At times, revenue recognition occurs before the billing, resulting in an unbilled receivable, which represents a contract asset. The contract asset is a component of accounts receivable and other assets for the current and non-current portions, respectively. When the Company receives advances or deposits from customers before revenue is recognized, this results in a contract liability. It can take up to two and half years from the time of order to revenue recognition due to the Company’s long sales cycle. Changes in the contract assets and contract liabilities are as follows (dollars in thousands): September 30, June 30, Change Amount Amount $ % Contract Assets: Unbilled accounts receivable – current (1) $ 12,934 $ 13,325 ( 391 ) ( 2.9 %) Interest receivable – current (2) 394 493 ( 99 ) ( 20.1 %) Long-term accounts receivable (3) 5,492 5,301 191 3.6 % Interest receivable – non-current (3) 643 683 ( 40 ) ( 5.9 %) Contract Liabilities: Customer advances 17,983 25,290 ( 7,307 ) ( 28.9 %) Deferred revenue – current 69,948 75,375 ( 5,427 ) ( 7.2 %) Deferred revenue – non-current 28,453 24,694 3,759 15.2 % (1) Included in accounts receivable on the unaudited condensed consolidated balance sheets. (2) Included in prepaid expenses and other current assets on the unaudited condensed consolidated balance sheets. (3) Included in other assets on the unaudited condensed consolidated balance sheets. During the three months ended September 30, 2022, contract assets changed primarily due to changes in the timing of billings that occurred after revenues were recognized and changes in transactions with payment terms exceeding 12 months. During the three months ended September 30, 2022, contract liabilities changed due to changes in the timing of recognition of revenue for system sales for which the warranty has not yet started and was deferred and due to changes in transaction price. During the three months ended September 30, 2022, the Company recognized revenue of $ 34.9 million, which was included in the deferred revenue balances at June 30, 2022. During the three months ended September 30, 2021, the Company recognized revenue of $ 33.5 million, which was included in the deferred revenue balances at June 30, 2021. Remaining Performance Obligations Remaining performance obligations represent deferred revenue from open contracts for which performance has already started and the transaction price from executed contracts for which performance has not yet started. Service contracts in general are considered month-to-month contracts. As of September 30, 2022, total remaining performance obligations amounted to $ 1,107.2 million. Of this total amount, $ 66.1 million related to long-term warranty and non-cancellable post warranty services, which is the estimated revenue expected to be recognized over the remaining service period and warranty period for systems that have been delivered (the time bands reflect management’s best estimate of when the Company will transfer control to the customer and may change based on timing of shipment, readiness of customers’ facilities for installation, installation requirements, and availability of products). The Company has elected the practical expedient to not disclose the unsatisfied performance obligations of contracts with an original expected duration of one year or less. The following table represents the Company's remaining performance obligations related to long-term warranty and non-cancellable post warranty services as of September 30, 2022 (in thousands): Fiscal years of revenue recognition 2023 2024 2025 Thereafter Long-term warranty and non-cancellable post warranty services $ 22,378 $ 21,638 $ 12,789 $ 9,285 For the remaining $ 1,041.1 million of performance obligations ( i.e., open systems sales, upgrades, training and other miscellaneous items), the Company estimates 25 % to 27 % will be recognized in the next 12 months, and the remaining portion will be recognized thereafter. The Company’s historical experience indicates that some of its customers will cancel or renegotiate contracts as economic conditions change or when product offerings change during the long sales cycle. The Company anticipates a portion of its open contracts may never result in revenue recognition primarily due to the long sales cycle and factors outside of its control including changes in its customers' needs or financial condition, changes in government or health insurance reimbursement policies or changes to regulatory requirements. Based on historical experience and management's best estimate, approximately 16 % of the Company’s $ 988.6 million open system sales contracts as of September 30, 2022, may never result in revenue. Capitalized Contract Costs As of September 30, 2022, and June 30, 2022, the balance of capitalized costs to obtain a contract was $ 11.5 million and $ 11.4 million, respectively. The Company has classified the capitalized costs to obtain a contract as a component of prepaid expenses and other current assets and other assets with respect to the current and non-current portions of capitalized costs, respectively, on the unaudited condensed consolidated balance sheets. The Company incurred impairment losses of $ 0.2 million and $ 0.1 million during the three months ended September 30, 2022 and 2021, respectively. The Company recognized $ 0.9 million in expenses related to the amortization of the capitalized contract costs in both the three months ended September 30, 2022 and 2021, respectively.

Supplemental Financial Informat

Supplemental Financial Information	3 Months Ended
	Sep. 30, 2022
Supplemental Financial Information Disclosure [Abstract]
Supplemental Financial Information	Note 4. Supplemental Financial Information Balance Sheet Components Financing receivables A financing receivable is a contractual right to receive money, on demand or on fixed or determinable dates, that is recognized as an asset on the Company’s balance sheets. The Company’s financing receivables, consisting of its accounts receivable with contractual maturities of more than one year, totaled $ 2.6 million and $ 2.8 million as of September 30, 2022, and June 30, 2022, respectively, and are included in Other assets on the unaudited condensed consolidated balance sheets. The Company evaluates the credit quality of a customer at contract inception and monitors credit quality over the term of the underlying transactions. The Company performs a credit analysis for all new customers and reviews payment history, current order backlog, financial performance of the customers and other variables that augment or mitigate the inherent credit risk of a particular transaction. Such variables include the underlying value and liquidity of the collateral, the essential use of the equipment, the contract term and the inclusion of credit enhancements, such as guarantees, letters of credit or security deposits. The Company classifies accounts as high risk when it considers the financing receivable to be impaired or when management believes there is a significant near‑term risk of non‑payment. The Company performs an assessment each quarter of the allowance for credit losses related to its financing receivables. A summary of the Company’s financing receivables is presented as follows (in thousands): September 30, June 30, Financing receivables $ 5,717 $ 6,137 Allowance for credit losses ( 943 ) ( 943 ) Total, net $ 4,774 $ 5,194 Reported as: Current $ 2,204 $ 2,435 Non-current 2,570 2,759 Total, net $ 4,774 $ 5,194 The Company did no t have any additions to the allowance for credit losses during the three months ended September 30, 2022 and 2021. Inventories Inventories consisted of the following (in thousands): September 30, June 30, Raw materials $ 65,296 $ 61,871 Work-in-process 19,673 16,367 Finished goods 67,655 64,016 Inventories $ 152,624 $ 142,254 Property and equipment, net Property and equipment, net consisted of the following (in thousands): September 30, June 30, Furniture and fixtures $ 1,784 $ 1,766 Computer and office equipment 8,309 8,605 Software 5,319 5,344 Leasehold improvements 26,520 26,659 Machinery and equipment 45,956 46,522 Construction in progress 2,154 2,999 90,042 91,895 Less: Accumulated depreciation ( 79,104 ) ( 79,210 ) Property and equipment, net $ 10,938 $ 12,685 Depreciation expense related to property and equipment for the three months ended September 30, 2022 and 2021 was $ 1.1 million. and $ 1.4 million, respectively. Accumulated Other Comprehensive Income (Loss) The changes in accumulated other comprehensive income (loss) are excluded from earnings and reported as a component of stockholders’ equity. The foreign currency translation adjustment results from those subsidiaries not using the U.S. Dollar as their functional currency since the majority of their economic activities are primarily denominated in their applicable local currency. Accordingly, all assets and liabilities related to these operations are translated to the U.S. Dollar at the current exchange rates at the end of each period. Revenues and expenses are translated at average exchange rates in effect during the period. The components of accumulated other comprehensive income (loss) in the stockholders' equity section of the Company’s unaudited condensed consolidated balance sheets are as follows (in thousands): September 30, June 30, Cumulative foreign currency translation adjustment $ ( 5,196 ) $ ( 1,541 ) Defined benefit pension obligation 3,947 3,947 Accumulated other comprehensive income (loss) $ ( 1,249 ) $ 2,406 Statements of Operations Other expense, net, consisted of the following (in thousands): Three Months Ended 2022 2021 Interest expense $ ( 2,262 ) $ ( 2,039 ) Foreign currency transaction loss ( 251 ) ( 769 ) Other expense, net ( 45 ) 140 Total other expense, net $ ( 2,558 ) $ ( 2,668 )

Leases

Leases	3 Months Ended
	Sep. 30, 2022
Leases [Abstract]
Leases	Note 5. Leases The Company has operating leases for corporate offices and warehouse facilities worldwide. Additionally, the Company leases cars, copy machines and laptops that are considered operating leases. Some of the Company’s leases are non-cancellable operating lease agreements with various expiration dates through June 2035. Certain lease agreements include options to renew or terminate the lease, which are not reasonably certain to be exercised and therefore are not factored into the determination of lease payments. In August 2022, the Company entered to a material lease agreement to extend the lease term at its office building and manufacturing facility in Madison, Wisconsin through 2035. Operating lease costs were $ 2.3 million and $ 2.3 million during the three months ended September 30, 2022 and 2021, respectively, not including $ 0.1 million and $ 0.1 million, respectively, of short-term operating lease costs. Cash paid for amounts included in the measurement of operating lease liabilities was $ 2.2 million and $ 2.5 million during the three months ended September 30, 2022 and 2021, respectively. Operating lease liabilities arising from obtaining operating right-of-use assets were $ 12.2 million and $ 0.9 million, during the three months ended September 30, 2022 and 2021, respectively. Operating lease right-of-use assets and operating lease obligations are represented in the table below (in thousands): September 30, June 30, Beginning balance operating lease right-of-use assets $ 16,798 $ 22,522 Lease asset added 12,203 3,522 Amortization for the year ( 2,212 ) ( 9,246 ) Ending balance operating lease right-of-use assets $ 26,789 $ 16,798 Beginning balance operating lease obligations $ 19,020 $ 25,609 Lease liability added 12,199 3,209 Repayment and interest accretion ( 2,232 ) ( 9,798 ) Ending balance operating lease obligations $ 28,987 $ 19,020 Current portion of operating lease obligations $ 4,864 $ 8,567 Non-current portion of operating lease obligations $ 24,123 $ 10,453 Maturities of operating lease liabilities as of September 30, 2022 are presented in the table below (dollars in thousands): Amount 2023 (remaining 9 months) $ 6,938 2024 2,678 2025 4,247 2026 3,344 2027 3,193 Thereafter 26,263 Total operating lease payments 46,663 Less: imputed interest ( 17,676 ) Present value of operating lease liabilities $ 28,987 Weighted average remaining lease term (in years) 8.5 Weighted average discount rate 8.6 %

Goodwill and Intangible Assets

Goodwill and Intangible Assets	3 Months Ended
	Sep. 30, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and Intangible Assets	Note 6. Goodwill and Intangible Assets Goodwill Activity related to goodwill consisted of the following (in thousands): September 30, June 30, Balance at the beginning of the period $ 57,840 $ 57,960 Currency translation ( 182 ) ( 120 ) Balance at the end of the period $ 57,658 $ 57,840 The Company did not identify any triggering events that would indicate a potential impairment of its goodwill as of September 30, 2022. The Company will continue to monitor its recorded goodwill for indicators of impairment. Purchased Intangible Assets The Company’s carrying amount of acquired intangible assets, net, is as follows (in thousands): September 30, 2022 June 30, 2022 Gross Accumulated Net Gross Accumulated Net Patent license $ 1,170 $ ( 956 ) $ 214 $ 1,170 $ ( 920 ) $ 250 The Company did not identify any triggering events that would indicate potential impairment of its definite-lived intangible and long-lived assets as of September 30, 2022. The estimated future amortization expense of acquired intangible assets as of September 30, 2022, is as follows (in thousands): Amount 2023 (remaining 9 months) $ 107 2024 107 Total estimated future amortization expense $ 214

Derivative Financial Instrument

Derivative Financial Instruments	3 Months Ended
	Sep. 30, 2022
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Derivative Financial Instruments	Note 7. Derivative Financial Instruments The Company utilizes foreign currency forward contracts with reputable financial institutions to manage its exposure of fluctuations in foreign currency exchange rates on certain intercompany balances and foreign currency denominated cash, customer receivables and liabilities. The Company does not use derivative financial instruments for speculative or trading purposes. These forward contracts are not designated as hedging instruments for accounting purposes. Principal hedged currencies include the Euro, Japanese Yen, Swiss Franc, and U.S. Dollar. The periods of these forward contracts range up to approximately three months and the notional amounts are intended to be consistent with changes in the underlying exposures. The Company intends to exchange foreign currencies for U.S. Dollars at maturity. The notional amount of the Company's outstanding forward currency exchange contracts September 30, 2022, and June 30, 2022, are as follows (in thousands): September 30, June 30, Swiss Franc $ 27,615 $ 27,910 Chinese Yuan 643 2,524 Euro 5,722 16,307 British Pound 1,024 3,699 Indian Rupee 3,088 3,728 Japanese Yen 6,527 14,167 Total outstanding forward currency exchange contracts $ 44,619 $ 68,335 The Company entered into the foreign currency forward contracts on September 30, 2022, and June 30, 2022, respectively, and therefore, there was no amount recorded on the unaudited condensed consolidated balance sheets. The following table provides information about the gain or loss associated with the Company’s derivative financial instruments (in thousands): Three Months Ended 2022 2021 Foreign currency exchange gain (loss) on forward contracts $ 1,659 $ ( 400 ) Foreign currency transactions loss ( 1,910 ) ( 369 )

Fair Value Measurements

Fair Value Measurements	3 Months Ended
	Sep. 30, 2022
Fair Value Disclosures [Abstract]
Fair Value Measurements	Note 8. Fair Value Measurements Fair value is an exit price representing the amount that would be received to sell an asset or paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The fair value hierarchy contains three levels of inputs that may be used to measure fair value, as follows: Level 1— Unadjusted quoted prices that are available in active markets for the identical assets or liabilities at the measurement date. Level 2— Other observable inputs available at the measurement date, other than quoted prices included in Level 1, either directly or indirectly, including: • Quoted prices for similar assets or liabilities in active markets; • Quoted prices for identical or similar assets in non-active markets; • Inputs other than quoted prices that are observable for the asset or liability; and • Inputs that are derived principally from or corroborated by other observable market data. Level 3— Unobservable inputs that cannot be corroborated by observable market data and require the use of significant management judgment. These values are generally determined using pricing models for which the assumptions utilize management’s estimates of market participant assumptions. Assets and Liabilities That Are Measured at Fair Value As of September 30, 2022, the Company had open currency forward contracts to purchase or sell foreign currencies with a stated, or notional, value of $ 44.6 million. The fair value of the underlying currency based upon the September 30, 2022, exchange rate was $ 44.6 million, which it considers to be a Level 2 fair value measurement. As of June 30, 2022, the Company had open currency forward contracts to purchase or sell foreign currencies with a stated, or notional, value of $ 68.3 million. The fair value of the underlying currency based upon the June 30, 2022, exchange rate was $ 68.3 million, which it considers to be a Level 2 fair value measurement. The Company’s debt is measured on a recurring basis using Level 2 inputs based upon observable inputs of the Company’s convertible debt. The Revolving Credit Facility (as defined in Note 10) and the Term Loan Facility (as defined in Note 10) reflects the bank quoted market rates, which the Company considers to be a Level 2 fair value measurement. The Company believes that the carrying value of these financial instruments approximate its estimated fair value based on the effective interest rate compared to the current market rate available to the Company and analyzed at quarter-end. The following table summarizes the carrying value and estimated fair value of the Term Loan Facility, the Revolving Credit Facility, the 3.75 % Convertible Senior Notes due July 2022 and the 3.75 % Convertible Senior Notes due July 2026 (in thousands) (see Note 10): September 30, June 30, Carrying Fair Carrying Fair 3.75 % Convertible Notes Due 2022 $ — $ — $ 2,863 $ 2,729 3.75 % Convertible Notes Due 2026 97,760 81,848 97,619 78,561 Term Loan Facility 73,565 73,565 74,988 74,988 Revolving Credit Facility 5,000 5,000 5,000 5,000 Total $ 176,325 $ 160,413 $ 180,470 $ 161,278

Commitments and Contingencies

Commitments and Contingencies	3 Months Ended
	Sep. 30, 2022
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Note 9. Commitments and Contingencies Litigation From time to time, the Company is involved in legal proceedings arising in the ordinary course of its business. The Company records a provision for a loss when it believes that it is both probable that a loss has been incurred and the amount can be reasonably estimated. To the extent there is a reasonable possibility that a loss exceeding amounts already recognized may be incurred and the amount of such additional loss would be material, we will either disclose the estimated additional loss or state that such an estimate cannot be made. Currently, management believes the Company does not have any probable and reasonably estimable material losses related to any current legal proceedings and claims. Although occasional adverse decisions or settlements may occur, management does not believe that an adverse determination with respect to any of these claims would individually or in the aggregate materially and adversely affect the Company’s financial condition or operating results. Litigation is inherently unpredictable and is subject to significant uncertainties, some of which are beyond the Company’s control. Should any of these estimates and assumptions change or prove to have been incorrect, the Company could incur significant charges related to legal matters that could have a material impact on its results of operations, financial position and cash flows. Indemnities Under the terms of the Company’s software license agreements with its customers, the Company agrees that in the event the software sold infringes upon any patent, copyright, trademark, or any other proprietary right of a third‑party, it will indemnify its customer licensees against any loss, expense, or liability from any damages that may be awarded against its customer. The Company includes this infringement indemnification in all of its software license agreements and selected managed services arrangements. In the event the customer cannot use the software or service due to infringement and the Company cannot obtain the right to use, replace or modify the license or service in a commercially feasible manner so that it no longer infringes, then the Company may terminate the license and provide the customer a refund of the fees paid by the customer for the infringing license or service. The Company has not recorded any liability associated with this indemnification, as it is not aware of any pending or threatened actions that represent probable losses as of September 30, 2022. The Company enters into standard indemnification agreements with its landlords and all superior mortgagees and their respective directors, officers’ agents, and employees in the ordinary course of business. Pursuant to these agreements, the Company will indemnify, hold harmless, and agree to reimburse the indemnified party for losses suffered or incurred by the indemnified party, generally the landlords, in connection with any loss, accident, injury, or damage by any third‑party with respect to the leased facilities. The term of these indemnification agreements is from the commencement of the lease agreements until termination of the lease agreements. The maximum potential amount of future payments the Company could be required to make under these indemnification agreements is unlimited; however, historically, the Company has not incurred claims or costs to defend lawsuits or settle claims related to these indemnification agreements. The Company has not recorded any liability associated with its indemnification agreements as it is not aware of any pending or threatened actions that represent probable losses as of September 30, 2022. Guarantees As of September 30, 2022, and June 30, 2022, the Company had various bank guarantees totaling $ 1.2 million and $ 1.2 million, respectively, primarily related to bidding processes with customers. Royalty Agreement The Company enters into software license agreements with third parties that may require royalty payments for each license used. In connection with such agreements, the Company recorded royalty costs of $ 0.5 million and $ 0.4 million during the three months ended September 30, 2022 and 2021, respectively, which were recorded in cost of revenue or deferred cost of revenue. The Company had approximately $ 2.5 million and $ 2.4 million accrued liabilities as of September 30, 2022, and June 30, 2022 , respectively, related to royalty agreements.

Debt

Debt	3 Months Ended
	Sep. 30, 2022
Debt Disclosure [Abstract]
Debt	Note 10. Debt 3.75% Convertible Senior Notes due July 2022 As of June 30, 2022, the $ 2.9 million aggregate principal amount of the 3.75 % Convertible Senior Notes due July 2022 (the “ 3.75 % Convertible Notes due 2022”) remained outstanding. In July 2022, the remaining outstanding amount of the 3.75 % Convertible Senior Notes due 2022 was repaid in cash. 3.75% Convertible Senior Notes due July 2026 In May 2021, the Company issued $ 100.0 million aggregate principal amount of its 3.75 % Convertible Senior Notes due July 2026 (the “ 3.75 % Convertible Notes due 2026”) under an indenture between the Company and The Bank of New York Mellon Trust Company, N.A., as trustee. As of September 30, 2022 , the if-converted value of its 3.75 % Convertible Notes due 2026 did not exceed the outstanding principal amount. Credit Facilities As of September 30, 2022, $ 5.0 million of aggregate principal amount was outstanding under the Company's $ 40.0 million revolving credit facility (the “Revolving Credit Facility”), $ 74.5 million aggregate principal amount was outstanding under the Company's five-year $ 80.0 million term loan ( the "Term Loan Facility") and $ 0.9 million of associated unamortized debt costs. As of June 30, 2022, $ 5.0 million of aggregate principal amount was outstanding under the Revolving Credit Facility, $ 76.0 million aggregate principal amount was outstanding under the Term Loan Facility and $ 1.0 million of associated unamortized debt costs. The following table presents the carrying value of the Notes, the Revolving Credit Facility, and the Term Loan Facility (in thousands): As of September 30, 2022 Revolving 3.75% Term Loan Total Principal amount of the Notes $ 5,000 $ 100,000 $ 74,500 $ 179,500 Unamortized debt costs — ( 2,240 ) ( 935 ) ( 3,175 ) Net carrying amount $ 5,000 $ 97,760 $ 73,565 $ 176,325 Reported as: Short-term debt $ 5,705 Long-term debt 170,620 Total debt $ 176,325 As of June 30, 2022 Revolving 3.75% 3.75% Term Loan Total Principal amount of the Notes $ 5,000 $ 2,865 $ 100,000 $ 76,000 $ 183,865 Unamortized debt costs — ( 1 ) ( 2,381 ) ( 1,013 ) ( 3,395 ) Net carrying amount $ 5,000 $ 2,864 $ 97,619 $ 74,987 $ 180,470 Reported as: Short-term debt $ 8,563 Long-term debt 171,907 Total debt $ 180,470 A summary of interest expense on the Notes and Credit Facilities is as follows (in thousands): Three Months Ended 2022 2021 Interest expense related to contractual interest coupon $ 2,032 $ 1,877 Interest expense related to amortization of debt issuance costs 219 156 Total $ 2,251 $ 2,033

Share-Based Compensation

Share-Based Compensation	3 Months Ended
	Sep. 30, 2022
Share-Based Payment Arrangement [Abstract]
Share-Based Compensation	Note 11. Share-Based Compensation The following table presents details of share-based compensation expenses by functional line item noted within the Company's operating expenses (in thousands): Three Months Ended 2022 2021 Cost of revenue $ 366 $ 372 Research and development 368 339 Selling and marketing 486 443 General and administrative 1,696 1,362 Total share-based compensation $ 2,916 $ 2,516

Net Loss Per Common Share

Net Loss Per Common Share	3 Months Ended
	Sep. 30, 2022
Earnings Per Share [Abstract]
Net Loss Per Common Share	Note 12. Net Loss Per Common Share The Company reports both basic and diluted income (loss) per share, which is based on the weighted average number of common shares outstanding during the period. A reconciliation of the numerator and denominator used in the calculation of basic and diluted net loss per common share follows (in thousands, except for per share amounts): Three Months Ended 2022 2021 Numerator: Net loss $ ( 5,449 ) $ ( 1,028 ) Denominator: Weighted average shares outstanding - basic 93,529 90,838 Weighted average shares outstanding - diluted 93,529 90,838 Basic net loss per share $ ( 0.06 ) $ ( 0.01 ) Diluted net loss per share $ ( 0.06 ) $ ( 0.01 ) The potentially dilutive shares of the Company’s common stock resulting from the assumed exercise of outstanding stock options, the vesting of Restricted Stock Units (RSU), Performance Stock Units (PSU), and the purchase of shares under the Employee Stock Purchase Program, as determined under the treasury stock method, are excluded from the computation of diluted net income (loss) per share when their effect would have been anti‑dilutive. Additionally, the outstanding 3.75 % Convertible Notes due 2022 and the 3.75 % Convertible Notes due 2026 (collectively, the “Notes”) are included in the calculation of diluted net income per share only if their inclusion is dilutive for periods during which the notes were outstanding. The following table sets forth all potentially dilutive securities excluded from the computation in the table above because their effect would have been anti-dilutive (in thousands): As of September 30, 2022 2021 Stock options 7,046 6,674 RSUs and PSUs 5,325 3,957 Notes 17,056 17,557 29,427 28,188

Segment Information

Segment Information	3 Months Ended
	Sep. 30, 2022
Segment Reporting [Abstract]
Segment Information	Note 13. Segment Information The Company has one operating and reporting segment (oncology systems group), which develops, manufactures and markets proprietary medical devices used in radiation therapy for the treatment of cancer patients. The Company’s Chief Executive Officer, its Chief Operating Decision Maker, reviews financial information presented on a consolidated basis for purposes of making operating decisions and assessing financial performance. The Company does not assess the performance of its individual product lines on measures of profit or loss, or asset-based metrics. Therefore, the information below is presented only for revenues and long-lived tangible assets by geographic area. Disaggregation of Revenues The Company disaggregates its revenues from contracts by geographic region, as the Company believes this best depicts how the nature, amount, timing and uncertainty of revenues and cash flows are affected by economic factors. Additionally, the Company typically recognizes revenue at a point in time for product revenue and recognizes revenue over time for service revenue. Revenues attributed to a country or region is based on the shipping addresses of the Company’s customers. The following summarizes revenue by geographic region (in thousands): Three Months Ended 2022 2021 Americas $ 27,285 $ 33,968 Europe, Middle East, India and Africa 36,746 30,100 Asia Pacific, excluding Japan and China 7,974 3,920 Japan 13,000 10,398 China 11,488 29,056 Total $ 96,493 $ 107,442 Disaggregation of Long-Lived Assets Information regarding geographic areas in which the Company has long-lived tangible assets is as follows (in thousands): September 30, June 30, 2022 2022 Americas $ 9,713 $ 11,251 Europe, Middle East, India and Africa 214 228 Asia Pacific, excluding Japan and China 221 272 Japan 213 265 China 577 669 Total $ 10,938 $ 12,685

Joint Venture

Joint Venture	3 Months Ended
	Sep. 30, 2022
Equity Method Investments and Joint Ventures [Abstract]
Joint Venture	Note 14. Joint Venture The Company applies the equity method of accounting to its ownership interest in the JV as the Company has the ability to exercise significant influence over the JV but lacks controlling financial interest and is not the primary beneficiary. The Company recognizes revenue on sales to the JV in the current period, eliminating a portion of profit to the extent goods sold have not been sold through by the JV to an end customer at the end of such reporting period. As of September 30, 2022, the Company owned a 49 % interest in the JV, which is reported as an Investment in joint venture on the Company’s unaudited condensed consolidated balance sheets. The following table shows the reconciliation between the carrying value of its investment in the JV and its proportional share of the underlying equity in net assets of the JV (in thousands): September 30, June 30, Carrying value of investment in joint venture $ 12,776 $ 13,879 Deferred intra-entity profit margin 5,495 5,456 Equity method goodwill ( 4,720 ) ( 4,720 ) Proportional share of equity investment in joint venture $ 13,551 $ 14,615 As of September 30, 2022, and June 30, 2022, the Company’s carrying value of the investment in the JV was adjusted for the Company's proportional share of the investee's currency translation adjustment by $ 0.3 million and $ 1.0 million, respectively. No impairment was identified as of September 30, 2022, to the equity method goodwill of the JV. Summarized financial information of the JV is based on a one-quarter lag due to the timing of the availability of the JV’s financial records is as follows (in thousands): Statement of Operations Data: Three Months Ended June 30, 2022 Three Months Ended June 30, 2021 Revenue $ 26,740 $ 7,669 Gross Profit 4,596 2,340 Net loss ( 752 ) ( 693 ) Net loss attributable to the Company ( 368 ) ( 340 ) Summarized Balance Sheet Data: As of As of Assets Current assets $ 72,241 $ 31,759 Non current assets 19,701 22,763 Total assets $ 91,942 $ 54,522 Liabilities and Stockholders' Equity Current liabilities $ 63,006 $ 24,445 Non current liabilities 862 1,300 Stockholders' equity 28,074 28,777 Total liabilities and stockholders' equity $ 91,942 $ 54,522 As of September 30, 2022, and June 30, 2022, the Company has $ 5.5 million and $ 5.4 million, respectively, of deferred intra-entity profit margin from sales on its unaudited condensed consolidated balance sheets. The following table shows the activity of the Company’s deferred intra-entity profit margin from sales (in thousands): Three Months Ended 2022 2021 Previously deferred intra-entity profit margin from sales - recognized $ ( 2,348 ) $ ( 215 ) Intra-entity profit margin from sales - deferred 2,387 1,953 Total change in deferred intra-entity profit margin from sales $ 39 $ 1,738

Income Tax

Income Tax	3 Months Ended
	Sep. 30, 2022
Income Tax Disclosure [Abstract]
Income Tax	Note 15. Income Tax On a quarterly basis, the Company provides for income taxes based upon an estimated annual effective income tax rate. The Company recognized income tax expense of $ 0.3 million and $ 0.4 million for the three months ended September 30, 2022 and 2021 respectively, primarily related to foreign taxes. Starting in fiscal year 2019, certain income earned by controlling foreign corporations (“CFCs”) must be included in the gross income of the CFC’s U.S. shareholder. The income required to be included in gross income is referred to as global intangible low tax income (“GILTI”) and is defined under IRC Section 951A as the excess of the shareholder’s net CFC tested income over the net deemed tangible income return. The GILTI inclusion amount is expected to be fully absorbed by net operating losses carryforward and is not expected to cause the Company to be in a U.S. taxable income position for fiscal year 2023. On August 16, 2022, President Biden signed the Inflation Reduction Act of 2022 (the "Inflation Act") into law. The Inflation Act contains certain tax measures, including a corporate alternative minimum tax of 15 % on some large corporations and an excise tax of 1 % on corporate stock buy-backs. The various provisions of the Inflation Act do not have a material impact on the Company’s consolidated financial statements. As of September 30, 2022, the Company’s gross unrecognized tax benefi ts was $ 19.8 million, of which $ 19.6 mil lion would not affect income tax expense before consideration of any valuation allowance. The Company does not expect its unrecognized tax benefits to change significantly over the next 12 months . Interest and penalties accrued on unrecognized tax benefits is recorded as a component of income tax expense.

Subsequent Events

Subsequent Events	3 Months Ended
	Sep. 30, 2022
Subsequent Events [Abstract]
Subsequent Events	Note 16. Subsequent Events On October 28, 2022, the Company entered into the First Amendment to Credit Agreement (the “Amendment”) in respect of its Credit Agreement for its Revolving Credit Facility and Term Loan Facility (the “Existing Credit Agreement”) among the Company, the financial institutions party thereto as lenders and issuing lenders and Silicon Valley Bank as administrative agent, issuing lender and swingline lender. The principal purpose of the Amendment is to relax the requirements of the financial maintenance covenants under the Existing Credit Agreement for the fiscal quarter ending December 31, 2022 through the end of the fiscal quarter ending June 30, 2023.

The Company and its Significa_2

The Company and its Significant Accounting Policies (Policies)	3 Months Ended
	Sep. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation	Basis of Presentation The unaudited condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All significant inter-company transactions and balances have been eliminated in consolidation. The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with United States generally accepted accounting principles (“GAAP”), pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”). Certain information and note disclosures have been condensed or omitted pursuant to such rules and regulations. The unaudited condensed consolidated financial statements have been prepared on the same basis as the annual financial statements and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary for a fair presentation of the periods presented. The results for the three months ended September 30, 2022, are not necessarily indicative of the results to be expected for the fiscal year ending June 30, 2023, or for any other future interim period or fiscal year. These unaudited condensed consolidated financial statements should be read in conjunction with the Company’s audited consolidated financial statements and accompanying notes for the fiscal year ended June 30, 2022 included in the Company’s Annual Report on Form 10-K filed with the SEC on August 17, 2022.
Risks and Uncertainties	Risks and Uncertainties The ongoing COVID-19 pandemic has created significant global economic uncertainty, adversely impacted the business of the Company's customers, partners and vendors, contributed to supply chain and labor issues, and has impacted its business and results of operations in the past and could further impact its results of operations and cash flows in the future. The Company is also subject to risks and uncertainties caused by events with significant macroeconomic impacts, including, but not limited to, the Russian invasion of Ukraine, inflation, actions taken to counter inflation and foreign currency exchange rate fluctuations. These conditions have created and may continue to create significant disruptions with respect to demand for the Company's products and services; the operating procedures and workflow of its customers, particularly hospitals; its ability to continue to manufacture its products; and the reliability of its supply chain, which have impacted and could continue to impact its revenue, expenses and operating results.
Use of Estimates	Use of Estimates The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, expenses, and related disclosures at the date of the financial statements. The Company assessed certain accounting matters that generally require consideration of forecasted financial information in context with the information reasonably available to the Company. Key estimates and assumptions made by the Company relate to revenue recognition and the assessment of stand-alone selling price, assessment of recoverability of goodwill, valuation of our equity method investment CNNC Accuray (Tianjin) Medical Technology Co. Ltd., the Company’s joint venture in China (the “JV”) , valuation of inventories, annual performance related bonuses, allowance for credit losses and loss contingencies. Actual results could differ materially from those estimates.
Significant Accounting Policies	Significant Accounting Policies There have been no changes in the Company’s significant accounting policies during the three months ended September 30, 2022, compared to the significant accounting policies described in its Annual Report on Form 10-K for the fiscal year ended June 30, 2022 .

Recent Accounting Pronounceme_2

Recent Accounting Pronouncements (Policies)	3 Months Ended
	Sep. 30, 2022
Accounting Pronouncements Not Yet Effective
Accounting Pronouncement Not Yet Effective	Accounting Pronouncement Not Yet Effective In March 2020, the FASB issued an update (ASU 2020-04) establishing Accounting Standards Codification (“ASC”) Topic 848, Reference Rate Reform. ASU 2020-04 contains practical expedients for reference rate reform related activities that impact debt, leases, derivatives and other contracts. The guidance in ASU 2020-04 is optional and may be elected over time as reference rate reform activities occur. The Company’s Term Loan Facility and Revolving Credit Facility applies Eurodollar rate LIBOR to the variable component of the interest rate, or if a Benchmark transition event, or an early opt-in election, as applicable occurred a transition to the use of the Secured Overnight Financing Rate ("SOFR") to replace such rate. This accounting standard update was effective upon issuance and may be applied prospectively through December 31, 2022. In October 2022, the Company will begin to use the SOFR to calculate the variable component of the interest rate for its Term Loan Facility and Revolving Credit Facility. The change to SOFR will not have a material impact on the Company's financial statements.

Revenue (Tables)

Revenue (Tables)	3 Months Ended
	Sep. 30, 2022
Revenue from Contract with Customer [Abstract]
Summary of Contract with Customer, Asset and Liability	Changes in the contract assets and contract liabilities are as follows (dollars in thousands): September 30, June 30, Change Amount Amount $ % Contract Assets: Unbilled accounts receivable – current (1) $ 12,934 $ 13,325 ( 391 ) ( 2.9 %) Interest receivable – current (2) 394 493 ( 99 ) ( 20.1 %) Long-term accounts receivable (3) 5,492 5,301 191 3.6 % Interest receivable – non-current (3) 643 683 ( 40 ) ( 5.9 %) Contract Liabilities: Customer advances 17,983 25,290 ( 7,307 ) ( 28.9 %) Deferred revenue – current 69,948 75,375 ( 5,427 ) ( 7.2 %) Deferred revenue – non-current 28,453 24,694 3,759 15.2 % (1) Included in accounts receivable on the unaudited condensed consolidated balance sheets. (2) Included in prepaid expenses and other current assets on the unaudited condensed consolidated balance sheets. (3) Included in other assets on the unaudited condensed consolidated balance sheets.
Schedule of Remaining Performance Obligations related to Warranty	The following table represents the Company's remaining performance obligations related to long-term warranty and non-cancellable post warranty services as of September 30, 2022 (in thousands): Fiscal years of revenue recognition 2023 2024 2025 Thereafter Long-term warranty and non-cancellable post warranty services $ 22,378 $ 21,638 $ 12,789 $ 9,285

Supplemental Financial Inform_2

Supplemental Financial Information (Tables)	3 Months Ended
	Sep. 30, 2022
Supplemental Financial Information Disclosure [Abstract]
Schedule of financing receivables	A summary of the Company’s financing receivables is presented as follows (in thousands): September 30, June 30, Financing receivables $ 5,717 $ 6,137 Allowance for credit losses ( 943 ) ( 943 ) Total, net $ 4,774 $ 5,194 Reported as: Current $ 2,204 $ 2,435 Non-current 2,570 2,759 Total, net $ 4,774 $ 5,194
Schedule of inventories	Inventories consisted of the following (in thousands): September 30, June 30, Raw materials $ 65,296 $ 61,871 Work-in-process 19,673 16,367 Finished goods 67,655 64,016 Inventories $ 152,624 $ 142,254
Schedule of property and equipment, net	Property and equipment, net consisted of the following (in thousands): September 30, June 30, Furniture and fixtures $ 1,784 $ 1,766 Computer and office equipment 8,309 8,605 Software 5,319 5,344 Leasehold improvements 26,520 26,659 Machinery and equipment 45,956 46,522 Construction in progress 2,154 2,999 90,042 91,895 Less: Accumulated depreciation ( 79,104 ) ( 79,210 ) Property and equipment, net $ 10,938 $ 12,685
Schedule of accumulated other comprehensive income (loss) in the stockholders' equity section	The components of accumulated other comprehensive income (loss) in the stockholders' equity section of the Company’s unaudited condensed consolidated balance sheets are as follows (in thousands): September 30, June 30, Cumulative foreign currency translation adjustment $ ( 5,196 ) $ ( 1,541 ) Defined benefit pension obligation 3,947 3,947 Accumulated other comprehensive income (loss) $ ( 1,249 ) $ 2,406
Schedule of statement of operations	Other expense, net, consisted of the following (in thousands): Three Months Ended 2022 2021 Interest expense $ ( 2,262 ) $ ( 2,039 ) Foreign currency transaction loss ( 251 ) ( 769 ) Other expense, net ( 45 ) 140 Total other expense, net $ ( 2,558 ) $ ( 2,668 )

Leases (Tables)

Leases (Tables)	3 Months Ended
	Sep. 30, 2022
Leases [Abstract]
Schedule of Operating Lease Right-of-use Assets and Operating Lease Obligations	Operating lease right-of-use assets and operating lease obligations are represented in the table below (in thousands): September 30, June 30, Beginning balance operating lease right-of-use assets $ 16,798 $ 22,522 Lease asset added 12,203 3,522 Amortization for the year ( 2,212 ) ( 9,246 ) Ending balance operating lease right-of-use assets $ 26,789 $ 16,798 Beginning balance operating lease obligations $ 19,020 $ 25,609 Lease liability added 12,199 3,209 Repayment and interest accretion ( 2,232 ) ( 9,798 ) Ending balance operating lease obligations $ 28,987 $ 19,020 Current portion of operating lease obligations $ 4,864 $ 8,567 Non-current portion of operating lease obligations $ 24,123 $ 10,453
Schedule of Maturities of Operating Lease Liabilities	Maturities of operating lease liabilities as of September 30, 2022 are presented in the table below (dollars in thousands): Amount 2023 (remaining 9 months) $ 6,938 2024 2,678 2025 4,247 2026 3,344 2027 3,193 Thereafter 26,263 Total operating lease payments 46,663 Less: imputed interest ( 17,676 ) Present value of operating lease liabilities $ 28,987 Weighted average remaining lease term (in years) 8.5 Weighted average discount rate 8.6 %

Goodwill and Intangible Assets

Goodwill and Intangible Assets (Tables)	3 Months Ended
	Sep. 30, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of goodwill	Activity related to goodwill consisted of the following (in thousands): September 30, June 30, Balance at the beginning of the period $ 57,840 $ 57,960 Currency translation ( 182 ) ( 120 ) Balance at the end of the period $ 57,658 $ 57,840
Schedule of carrying amount of acquired intangible assets, net	The Company’s carrying amount of acquired intangible assets, net, is as follows (in thousands): September 30, 2022 June 30, 2022 Gross Accumulated Net Gross Accumulated Net Patent license $ 1,170 $ ( 956 ) $ 214 $ 1,170 $ ( 920 ) $ 250
Schedule of estimated future amortization expense of acquired intangible assets	The estimated future amortization expense of acquired intangible assets as of September 30, 2022, is as follows (in thousands): Amount 2023 (remaining 9 months) $ 107 2024 107 Total estimated future amortization expense $ 214

Derivative Financial Instrume_2

Derivative Financial Instruments (Tables)	3 Months Ended
	Sep. 30, 2022
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Summary of Outstanding Forward Currency Exchange Contracts	The notional amount of the Company's outstanding forward currency exchange contracts September 30, 2022, and June 30, 2022, are as follows (in thousands): September 30, June 30, Swiss Franc $ 27,615 $ 27,910 Chinese Yuan 643 2,524 Euro 5,722 16,307 British Pound 1,024 3,699 Indian Rupee 3,088 3,728 Japanese Yen 6,527 14,167 Total outstanding forward currency exchange contracts $ 44,619 $ 68,335
Schedule of Gain (loss) Associated With the Company's Derivative Financial Instruments	The following table provides information about the gain or loss associated with the Company’s derivative financial instruments (in thousands): Three Months Ended 2022 2021 Foreign currency exchange gain (loss) on forward contracts $ 1,659 $ ( 400 ) Foreign currency transactions loss ( 1,910 ) ( 369 )

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	3 Months Ended
	Sep. 30, 2022
Fair Value Disclosures [Abstract]
Summary of Carrying Values and Estimated Fair Values of Short-Term and Long-Term Debt	The following table summarizes the carrying value and estimated fair value of the Term Loan Facility, the Revolving Credit Facility, the 3.75 % Convertible Senior Notes due July 2022 and the 3.75 % Convertible Senior Notes due July 2026 (in thousands) (see Note 10): September 30, June 30, Carrying Fair Carrying Fair 3.75 % Convertible Notes Due 2022 $ — $ — $ 2,863 $ 2,729 3.75 % Convertible Notes Due 2026 97,760 81,848 97,619 78,561 Term Loan Facility 73,565 73,565 74,988 74,988 Revolving Credit Facility 5,000 5,000 5,000 5,000 Total $ 176,325 $ 160,413 $ 180,470 $ 161,278

Debt (Tables)

Debt (Tables)	3 Months Ended
	Sep. 30, 2022
Debt Disclosure [Abstract]
Schedule of Carrying Values of all Debt	The following table presents the carrying value of the Notes, the Revolving Credit Facility, and the Term Loan Facility (in thousands): As of September 30, 2022 Revolving 3.75% Term Loan Total Principal amount of the Notes $ 5,000 $ 100,000 $ 74,500 $ 179,500 Unamortized debt costs — ( 2,240 ) ( 935 ) ( 3,175 ) Net carrying amount $ 5,000 $ 97,760 $ 73,565 $ 176,325 Reported as: Short-term debt $ 5,705 Long-term debt 170,620 Total debt $ 176,325 As of June 30, 2022 Revolving 3.75% 3.75% Term Loan Total Principal amount of the Notes $ 5,000 $ 2,865 $ 100,000 $ 76,000 $ 183,865 Unamortized debt costs — ( 1 ) ( 2,381 ) ( 1,013 ) ( 3,395 ) Net carrying amount $ 5,000 $ 2,864 $ 97,619 $ 74,987 $ 180,470 Reported as: Short-term debt $ 8,563 Long-term debt 171,907 Total debt $ 180,470
Summary of Interest Expense on Notes and Credit Facilities	A summary of interest expense on the Notes and Credit Facilities is as follows (in thousands): Three Months Ended 2022 2021 Interest expense related to contractual interest coupon $ 2,032 $ 1,877 Interest expense related to amortization of debt issuance costs 219 156 Total $ 2,251 $ 2,033

Share-Based Compensation (Table

Share-Based Compensation (Tables)	3 Months Ended
	Sep. 30, 2022
Share-Based Payment Arrangement [Abstract]
Summary of Share-based Compensation Expenses by Functional Line Item Noted Within Company's Operating Expenses	The following table presents details of share-based compensation expenses by functional line item noted within the Company's operating expenses (in thousands): Three Months Ended 2022 2021 Cost of revenue $ 366 $ 372 Research and development 368 339 Selling and marketing 486 443 General and administrative 1,696 1,362 Total share-based compensation $ 2,916 $ 2,516

Net Loss Per Common Share (Tabl

Net Loss Per Common Share (Tables)	3 Months Ended
	Sep. 30, 2022
Earnings Per Share [Abstract]
Schedule of reconciliation of the numerator and denominator used in the calculation of basic and diluted net loss per common share	A reconciliation of the numerator and denominator used in the calculation of basic and diluted net loss per common share follows (in thousands, except for per share amounts): Three Months Ended 2022 2021 Numerator: Net loss $ ( 5,449 ) $ ( 1,028 ) Denominator: Weighted average shares outstanding - basic 93,529 90,838 Weighted average shares outstanding - diluted 93,529 90,838 Basic net loss per share $ ( 0.06 ) $ ( 0.01 ) Diluted net loss per share $ ( 0.06 ) $ ( 0.01 )
Schedule of all potentially dilutive securities excluded from the computation of basic and diluted net income per common share	The following table sets forth all potentially dilutive securities excluded from the computation in the table above because their effect would have been anti-dilutive (in thousands): As of September 30, 2022 2021 Stock options 7,046 6,674 RSUs and PSUs 5,325 3,957 Notes 17,056 17,557 29,427 28,188

Segment Information (Tables)

Segment Information (Tables)	3 Months Ended
	Sep. 30, 2022
Segment Reporting [Abstract]
Summary of Revenue by Geographic Region	Revenues attributed to a country or region is based on the shipping addresses of the Company’s customers. The following summarizes revenue by geographic region (in thousands): Three Months Ended 2022 2021 Americas $ 27,285 $ 33,968 Europe, Middle East, India and Africa 36,746 30,100 Asia Pacific, excluding Japan and China 7,974 3,920 Japan 13,000 10,398 China 11,488 29,056 Total $ 96,493 $ 107,442
Schedule of Geographic Areas in Which the Company has Long Lived Tangible Assets	Information regarding geographic areas in which the Company has long-lived tangible assets is as follows (in thousands): September 30, June 30, 2022 2022 Americas $ 9,713 $ 11,251 Europe, Middle East, India and Africa 214 228 Asia Pacific, excluding Japan and China 221 272 Japan 213 265 China 577 669 Total $ 10,938 $ 12,685

Joint Venture (Tables)

Joint Venture (Tables)	3 Months Ended
	Sep. 30, 2022
Equity Method Investments and Joint Ventures [Abstract]
Summary of Reconciliation Between the Carrying Value of Investment and Proportional Share of Underlying Equity in Net Assets of Joint Ventures	The following table shows the reconciliation between the carrying value of its investment in the JV and its proportional share of the underlying equity in net assets of the JV (in thousands): September 30, June 30, Carrying value of investment in joint venture $ 12,776 $ 13,879 Deferred intra-entity profit margin 5,495 5,456 Equity method goodwill ( 4,720 ) ( 4,720 ) Proportional share of equity investment in joint venture $ 13,551 $ 14,615
Summary of Financial Information of Joint Ventures (Operations Data)	Summarized financial information of the JV is based on a one-quarter lag due to the timing of the availability of the JV’s financial records is as follows (in thousands): Statement of Operations Data: Three Months Ended June 30, 2022 Three Months Ended June 30, 2021 Revenue $ 26,740 $ 7,669 Gross Profit 4,596 2,340 Net loss ( 752 ) ( 693 ) Net loss attributable to the Company ( 368 ) ( 340 )
Summary of Financial Information of Joint Ventures (Balance Sheet Data)	Summarized Balance Sheet Data: As of As of Assets Current assets $ 72,241 $ 31,759 Non current assets 19,701 22,763 Total assets $ 91,942 $ 54,522 Liabilities and Stockholders' Equity Current liabilities $ 63,006 $ 24,445 Non current liabilities 862 1,300 Stockholders' equity 28,074 28,777 Total liabilities and stockholders' equity $ 91,942 $ 54,522
Schedule of Deferred Intra Entity Profit Margin from Sales	The following table shows the activity of the Company’s deferred intra-entity profit margin from sales (in thousands): Three Months Ended 2022 2021 Previously deferred intra-entity profit margin from sales - recognized $ ( 2,348 ) $ ( 215 ) Intra-entity profit margin from sales - deferred 2,387 1,953 Total change in deferred intra-entity profit margin from sales $ 39 $ 1,738

Revenue - Summary of Contract w

Revenue - Summary of Contract with Customer, Asset and Liability (Details) - USD ($) $ in Thousands		3 Months Ended
		Sep. 30, 2022	Jun. 30, 2022
Contract Assets:
Unbilled accounts receivable - current	[1]	$ 12,934	$ 13,325
Interest receivable - current	[2]	394	493
Long-term accounts receivable	[3]	5,492	5,301
Interest receivable - non-current	[3]	643	683
Contract Liabilities:
Customer advances		17,983	25,290
Deferred revenue – current		69,948	75,375
Deferred revenue – non-current		28,453	$ 24,694
Change in assets, value:
Change in unbilled accounts receivable – current, value	[1]	(391)
Change in interest receivable – current, value	[2]	(99)
Change in long-term accounts receivable, value	[3]	191
Change in Interest receivable – non-current, value	[3]	(40)
Change in liabilities, value:
Change in customer advances, value		(7,307)
Change in deferred revenue – current, value		(5,427)
Change in deferred revenue – non-current, value		$ (3,759)
Change in assets, percentage:
Change in unbilled accounts receivable – current, percentage	[1]	(2.90%)
Change in interest receivable – current, percentage	[2]	(20.10%)
Change in long-term accounts receivable, percentage	[3]	3.60%
Change in Interest receivable – non-current, percentage	[3]	(5.90%)
Change in liabilities, percentage:
Change in customer advances, percentage		(28.90%)
Change in deferred revenue – current, percentage		(7.20%)
Change in deferred revenue – non-current, percentage		15.20%
[1] Included in accounts receivable on the unaudited condensed consolidated balance sheets. Included in prepaid expenses and other current assets on the unaudited condensed consolidated balance sheets. Included in other assets on the unaudited condensed consolidated balance sheets.

Revenue - Additional Informatio

Revenue - Additional Information (Details) - USD ($) $ in Millions	3 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Jun. 30, 2022
Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items]
Recognition of deferred revenue	$ 34.9	$ 33.5
Remaining performance obligations amount	$ 1,107.2
Percentage of changes in operating results on entity's revenue	16%
Capitalized costs to obtain a contract	$ 11.5		$ 11.4
Impairment loss	0.2	0.1
Capitalized contract cost, amortization	0.9	$ 0.9
Long-term Warranty and Service
Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items]
Remaining performance obligations amount	66.1
Performance Obligations Other Than Warrant
Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items]
Remaining performance obligations amount	1,041.1
Performance Obligations Service Contracts
Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items]
Remaining performance obligations amount	$ 988.6

Revenue - Schedule of Remaining

Revenue - Schedule of Remaining Performance Obligations related to Warranty (Details) - Long-term Warranty and Service $ in Thousands	Sep. 30, 2022 USD ($)
2023	$ 22,378
2024	21,638
2025	12,789
Thereafter	$ 9,285

Revenue - Additional Informat_2

Revenue - Additional Information (Details1) - Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date: 2022-10-01	Sep. 30, 2022
Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items]
Remaining performance obligations recognized period	12 months
Minimum
Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items]
Remaining performance obligations percentage	25%
Maximum
Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items]
Remaining performance obligations percentage	27%

Supplemental Financial Inform_3

Supplemental Financial Information - Additional Information (Details) - USD ($)	3 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Jun. 30, 2022
Financing receivables
Accounts receivable with contractual maturities of more than one year	$ 2,570,000		$ 2,759,000
Financing receivables, additions	0	$ 0
Property and equipment, net
Depreciation expense	$ 1,100,000	$ 1,400,000

Supplemental Financial Inform_4

Supplemental Financial Information - Summary of Financing Receivables (Details) - USD ($) $ in Thousands	Sep. 30, 2022	Jun. 30, 2022
Financing receivables
Financing receivables	$ 5,717	$ 6,137
Allowance for credit losses	(943)	(943)
Total, net	4,774	5,194
Current	2,204	2,435
Non-current	$ 2,570	$ 2,759

Supplemental Financial Inform_5

Supplemental Financial Information - Summary of Inventories (Details) - USD ($) $ in Thousands	Sep. 30, 2022	Jun. 30, 2022
Inventory, Net [Abstract]
Raw materials	$ 65,296	$ 61,871
Work-in-process	19,673	16,367
Finished goods	67,655	64,016
Inventories	$ 152,624	$ 142,254

Supplemental Financial Inform_6

Supplemental Financial Information - Schedule of Property and Equipment, Net (Details) - USD ($) $ in Thousands	Sep. 30, 2022	Jun. 30, 2022
Property and equipment, net
Property and equipment, gross	$ 90,042	$ 91,895
Less: Accumulated depreciation	(79,104)	(79,210)
Property and equipment, net	10,938	12,685
Furniture and Fixtures
Property and equipment, net
Property and equipment, gross	1,784	1,766
Computer and Office Equipment
Property and equipment, net
Property and equipment, gross	8,309	8,605
Software
Property and equipment, net
Property and equipment, gross	5,319	5,344
Leasehold Improvements
Property and equipment, net
Property and equipment, gross	26,520	26,659
Machinery and Equipment
Property and equipment, net
Property and equipment, gross	45,956	46,522
Construction in Progress
Property and equipment, net
Property and equipment, gross	$ 2,154	$ 2,999

Supplemental Financial Inform_7

Supplemental Financial Information - Accumulated Other Comprehensive Income (Loss) (Details) - USD ($) $ in Thousands	Sep. 30, 2022	Jun. 30, 2022
Accumulated Other Comprehensive Income (Loss)
Cumulative foreign currency translation adjustment	$ (5,196)	$ (1,541)
Defined benefit pension obligation	3,947	3,947
Accumulated other comprehensive income (loss)	$ (1,249)	$ 2,406

Supplemental Financial Inform_8

Supplemental Financial Information - Schedule Of Statement Of Operations (Details) - USD ($) $ in Thousands	3 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Supplemental Financial Information Disclosure [Abstract]
Interest expense	$ (2,262)	$ (2,039)
Foreign currency transaction loss	(251)	(769)
Other expense, net	(45)	140
Total other expense, net	$ (2,558)	$ (2,668)

Leases - Additional Information

Leases - Additional Information (Details) - USD ($) $ in Millions	3 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Leases [Abstract]
Operating lease costs	$ 2.3	$ 2.3
Short-term operating lease costs	0.1	0.1
Cash paid for amounts included in the measurement of operating lease liabilities	2.2	2.5
Operating lease liabilities arising from obtaining operating right of-use assets	$ 12.2	$ 0.9

Leases - Schedule of Operating

Leases - Schedule of Operating Lease Right-of-use Assets and Operating Lease Obligations (Details) - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Sep. 30, 2022	Jun. 30, 2022
Leases [Abstract]
Beginning balance operating lease right-of-use assets	$ 16,798	$ 22,522
Lease asset added	12,203	3,522
Amortization for the year	(2,212)	(9,246)
Ending balance operating lease right-of-use assets	26,789	16,798
Beginning balance operating lease obligations	19,020	25,609
Lease liability added	12,199	3,209
Repayment and interest accretion	(2,232)	(9,798)
Ending balance operating lease obligations	28,987	19,020
Current portion of operating lease obligations	4,864	8,567
Non-current portion of operating lease obligations	$ 24,123	$ 10,453

Leases - Schedule of Maturities

Leases - Schedule of Maturities of Operating Lease Liabilities (Details) $ in Thousands	Sep. 30, 2022 USD ($)
Leases [Abstract]
2023 (remaining 9 months)	$ 6,938
2024	2,678
2025	4,247
2026	3,344
2027	3,193
Thereafter	26,263
Total operating lease payments	46,663
Less: imputed interest	(17,676)
Present value of operating lease liabilities	$ 28,987
Weighted average remaining lease term (in years)	8 years 6 months
Weighted average discount rate	8.60%

Goodwill and Intangible Asset_2

Goodwill and Intangible Assets - Schedule of Goodwill (Details) - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Sep. 30, 2022	Jun. 30, 2022
Changes in the carrying amount of goodwill
Balance at the beginning of the period	$ 57,840	$ 57,960
Currency translation	(182)	(120)
Balance at the end of the period	$ 57,658	$ 57,840

Goodwill and Intangible Asset_3

Goodwill and Intangible Assets - Schedule of Carrying Amount of Acquired Intangible Assets, Net (Details) - USD ($) $ in Thousands	Sep. 30, 2022	Jun. 30, 2022
Finite Lived Intangible Assets [Line Items]
Total estimated future amortization expense	$ 214	$ 250
Patent license
Finite Lived Intangible Assets [Line Items]
Gross Carrying Amount	1,170	1,170
Accumulated Amortization	(956)	(920)
Total estimated future amortization expense	$ 214	$ 250

Goodwill and Intangible Asset_4

Goodwill and Intangible Assets - Schedule of Estimated Future Amortization Expense of Acquired Intangible Assets (Details) - USD ($) $ in Thousands	Sep. 30, 2022	Jun. 30, 2022
Estimated future amortization expense of purchased intangible assets
2023 (remaining 9 months)	$ 107
2024	107
Total estimated future amortization expense	$ 214	$ 250

Derivative Financial Instrume_3

Derivative Financial Instruments - Additional Information (Details)	3 Months Ended
	Sep. 30, 2022
Maximum
Length of forward contracts	three months

Derivative Financial Instrume_4

Derivative Financial Instruments - Summary of Outstanding Forward Currency Exchange Contracts (Details) - Forward Currency Exchange Contracts - USD ($) $ in Thousands	Sep. 30, 2022	Jun. 30, 2022
Outstanding forward currency exchange contracts	$ 44,619	$ 68,335
Swiss Franc
Outstanding forward currency exchange contracts	27,615	27,910
Chinese Yuan
Outstanding forward currency exchange contracts	643	2,524
Euro
Outstanding forward currency exchange contracts	5,722	16,307
British Pound
Outstanding forward currency exchange contracts	1,024	3,699
Indian Rupee
Outstanding forward currency exchange contracts	3,088	3,728
Japanese Yen
Outstanding forward currency exchange contracts	$ 6,527	$ 14,167

Derivative Financial Instrume_5

Derivative Financial Instruments - Schedule of Gain (Loss) Associated with the Company's Derivative Financial Instruments (Details) - Other expense, net - USD ($) $ in Thousands	3 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Foreign currency exchange gain (loss) on forward contracts	$ (1,910)	$ (369)
Forward contracts
Foreign currency exchange gain (loss) on forward contracts	$ 1,659	$ (400)

Fair Value Measurements - Addit

Fair Value Measurements - Additional Information (Details) - Forward Currency Exchange Contracts - USD ($) $ in Thousands	Sep. 30, 2022	Jun. 30, 2022
Financial assets
Outstanding forward currency exchange contracts	$ 44,619	$ 68,335
Level 2
Financial assets
Fair value of currency contract based on exchange rate	$ 44,600	$ 68,300

Fair Value Measurements - Summa

Fair Value Measurements - Summary of Carrying Value and Estimated Fair Value of all Debt (Details) - USD ($) $ in Thousands	Sep. 30, 2022	Jun. 30, 2022
Carrying Value
Fair value measurement
Long term debt	$ 176,325	$ 180,470
Fair Value
Fair value measurement
Long term debt	160,413	161,278
Non-recurring basis | Carrying Value | Level 2 | 3.75% Convertible Notes Due 2022
Fair value measurement
Long term debt	0	2,863
Non-recurring basis | Carrying Value | Level 2 | 3.75% Convertible Notes Due 2026
Fair value measurement
Long term debt	97,760	97,619
Non-recurring basis | Fair Value | Level 2 | 3.75% Convertible Notes Due 2022
Fair value measurement
Long term debt	0	2,729
Non-recurring basis | Fair Value | Level 2 | 3.75% Convertible Notes Due 2026
Fair value measurement
Long term debt	81,848	78,561
Term Loan Facility | Non-recurring basis | Carrying Value | Level 2
Fair value measurement
Long term debt	73,565	74,988
Term Loan Facility | Non-recurring basis | Fair Value | Level 2
Fair value measurement
Long term debt	73,565	74,988
Revolving Credit Facility | Non-recurring basis | Carrying Value | Level 2
Fair value measurement
Long term debt	5,000	5,000
Revolving Credit Facility | Non-recurring basis | Fair Value | Level 2
Fair value measurement
Long term debt	$ 5,000	$ 5,000

Fair Value Measurements - Sum_2

Fair Value Measurements - Summary of Carrying Value and Estimated Fair Value of all Debt (Parenthetical) (Details)	Sep. 30, 2022	Aug. 31, 2022	Jun. 30, 2022	May 31, 2021
3.75% Convertible Notes Due 2022
Fair value measurement
Interest rate (as a percent)	3.75%	3.75%	3.75%
3.75% Convertible Notes Due 2026
Fair value measurement
Interest rate (as a percent)	3.75%		3.75%	3.75%

Commitments and Contingencies -

Commitments and Contingencies - Additional Information (Details) - USD ($) $ in Millions	3 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Jun. 30, 2022
License agreement | WARF (Wisconsin Alumni Research Foundation)
Loss Contingencies [Line Items]
Royalty costs	$ 0.5	$ 0.4
Royalty amount accrued	2.5		$ 2.4
Financial Guarantee | Various Customers
Loss Contingencies [Line Items]
Bank guarantees	$ 1.2		$ 1.2

Debt - Additional Information (

Debt - Additional Information (Details) - USD ($) $ in Thousands	3 Months Ended
	Sep. 30, 2022	Aug. 31, 2022	Jun. 30, 2022	May 31, 2021
Debt Instrument [Line Items]
Increase to accumulated deficit	$ (497,971)		$ (492,522)
Decrease to additional paid in capital	546,117		543,211
Principal amount of the Notes	179,500		183,865
Unamortized debt costs	(3,175)		(3,395)
Revolving Credit Facility
Debt Instrument [Line Items]
Credit facility borrowing capacity	40,000
Principal amount of the Notes	5,000		5,000
Unamortized debt costs	$ (900)		(1,000)
Term Loan
Debt Instrument [Line Items]
Term of loan	5 years
Credit facility borrowing capacity	$ 80,000
Principal amount of the Notes	$ 74,500		76,000
3.75% Convertible Notes Due 2022
Debt Instrument [Line Items]
Aggregate principal amount of debt issued			$ 2,900
Interest rate (as a percent)	3.75%	3.75%	3.75%
Principal amount of the Notes			$ 2,865
Unamortized debt costs			$ (1)
3.75% Convertible Notes Due 2026
Debt Instrument [Line Items]
Aggregate principal amount of debt issued				$ 100,000
Interest rate (as a percent)	3.75%		3.75%	3.75%
Principal amount of the Notes	$ 100,000		$ 100,000
Unamortized debt costs	$ (2,240)		$ (2,381)

Debt - Schedule of Carrying Val

Debt - Schedule of Carrying Values of All Debt (Details) - USD ($) $ in Thousands	Sep. 30, 2022	Jun. 30, 2022
Debt Instrument [Line Items]
Principal amount of the Notes	$ 179,500	$ 183,865
Unamortized debt costs	(3,175)	(3,395)
Net carrying amount	176,325	180,470
Reported as:
Short-term debt	5,705	8,563
Long-term debt	170,620	171,907
Net carrying amount	176,325	180,470
Revolving Credit Facility
Debt Instrument [Line Items]
Principal amount of the Notes	5,000	5,000
Unamortized debt costs	(900)	(1,000)
Net carrying amount	5,000	5,000
Reported as:
Net carrying amount	5,000	5,000
3.75% Convertible Notes Due 2022
Debt Instrument [Line Items]
Principal amount of the Notes		2,865
Unamortized debt costs		(1)
Net carrying amount		2,864
Reported as:
Net carrying amount		2,864
3.75% Convertible Notes Due 2026
Debt Instrument [Line Items]
Principal amount of the Notes	100,000	100,000
Unamortized debt costs	(2,240)	(2,381)
Net carrying amount	97,760	97,619
Reported as:
Net carrying amount	97,760	97,619
Term Loan Facility Due May 2026
Debt Instrument [Line Items]
Principal amount of the Notes	74,500	76,000
Unamortized debt costs	(935)	(1,013)
Net carrying amount	73,565	74,987
Reported as:
Net carrying amount	$ 73,565	$ 74,987

Debt - Summary of Interest Expe

Debt - Summary of Interest Expense on Notes and Credit Facilities (Details) - USD ($) $ in Thousands	3 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Debt Disclosure [Abstract]
Interest expense related to contractual interest coupon	$ 2,032	$ 1,877
Interest expense related to amortization of debt issuance costs	219	156
Total	$ 2,251	$ 2,033

Share-Based Compensation - Summ

Share-Based Compensation - Summary of Share-Based Compensation Expenses by Functional Line Item Noted Within Company's Operating Expenses (Details) - USD ($) $ in Thousands	3 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Share-based compensation expenses
Share-based compensation expense	$ 2,916	$ 2,516
Cost of revenue
Share-based compensation expenses
Share-based compensation expense	366	372
Research and development
Share-based compensation expenses
Share-based compensation expense	368	339
Selling and marketing
Share-based compensation expenses
Share-based compensation expense	486	443
General and administrative
Share-based compensation expenses
Share-based compensation expense	$ 1,696	$ 1,362

Net Loss Per Common Share - Sch

Net Loss Per Common Share - Schedule of reconciliation of the numerator and denominator used in the calculation of basic and diluted net income (loss) per common share (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Numerator:
Net loss	$ (5,449)	$ (1,028)
Denominator:
Weighted average shares outstanding - basic	93,529	90,838
Weighted average shares outstanding - diluted	93,529	90,838
Basic net loss per share	$ (0.06)	$ (0.01)
Diluted net loss per share	$ (0.06)	$ (0.01)

Net Loss Per Common Share - Add

Net Loss Per Common Share - Additional Information (Details)	3 Months Ended
	Sep. 30, 2022	Aug. 31, 2022	Jun. 30, 2022	May 31, 2021
3.75% Convertible Senior Notes due 2022
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Interest rate (as a percent)	3.75%	3.75%	3.75%
Convertible debt maturity period	2022
3.75% Convertible Notes Due 2026
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Interest rate (as a percent)	3.75%		3.75%	3.75%
Convertible debt maturity period	2026

Net Loss Per Common Share - S_2

Net Loss Per Common Share - Schedule of all potentially dilutive securities excluded from the computation of basic and diluted net income per common share (Details) - shares shares in Thousands	3 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Anti-dilutive securities excluded from the computation of diluted net income per share (in shares)	29,427	28,188
Stock options
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Anti-dilutive securities excluded from the computation of diluted net income per share (in shares)	7,046	6,674
RSUs and PSUs
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Anti-dilutive securities excluded from the computation of diluted net income per share (in shares)	5,325	3,957
Notes
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Anti-dilutive securities excluded from the computation of diluted net income per share (in shares)	17,056	17,557

Segment Information - Additiona

Segment Information - Additional Information (Details)	3 Months Ended
	Sep. 30, 2022 Segment
Segment Reporting [Abstract]
Number of operating segments	1
Number of reportable segments	1

Segment Information - Summary o

Segment Information - Summary of Revenue by Geographic Region (Details) - USD ($) $ in Thousands	3 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Segment Information
Total net revenue	$ 96,493	$ 107,442
Americas
Segment Information
Total net revenue	27,285	33,968
Europe, Middle East, India and Africa
Segment Information
Total net revenue	36,746	30,100
Asia Pacific, excluding Japan and China
Segment Information
Total net revenue	7,974	3,920
Japan
Segment Information
Total net revenue	13,000	10,398
China
Segment Information
Total net revenue	$ 11,488	$ 29,056

Segment Information - Schedule

Segment Information - Schedule of Geographic Areas in Which the Company has Long-Lived Tangible Assets (Details) - USD ($) $ in Thousands	Sep. 30, 2022	Jun. 30, 2022
Segment Information
Long lived tangible assets	$ 10,938	$ 12,685
Americas
Segment Information
Long lived tangible assets	9,713	11,251
Europe, Middle East, India and Africa
Segment Information
Long lived tangible assets	214	228
Asia Pacific, excluding Japan and China
Segment Information
Long lived tangible assets	221	272
Japan
Segment Information
Long lived tangible assets	213	265
China
Segment Information
Long lived tangible assets	$ 577	$ 669

Joint Venture - Additional Info

Joint Venture - Additional Information (Details) - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Sep. 30, 2022	Jun. 30, 2022
Schedule Of Equity Method Investments [Line Items]
Currency translation adjustment	$ (182)	$ (120)
Joint venture
Schedule Of Equity Method Investments [Line Items]
Percentage of ownership interest in joint venture	49%
Currency translation adjustment	$ 300	1,000
Deferred intra-entity profit margin from sales	5,500	$ 5,400
Impairment of goodwill	$ 0

Joint Venture - Summary of Reco

Joint Venture - Summary of Reconciliation Between the Carrying Value of Investment and Proportional Share of Underlying Equity in Net Assets of Joint Ventures (Details) - USD ($) $ in Thousands	Sep. 30, 2022	Jun. 30, 2022	Jun. 30, 2021
Schedule of Equity Method Investments [Line Items]
Goodwill	$ 57,658	$ 57,840	$ 57,960
Joint venture
Schedule of Equity Method Investments [Line Items]
Carrying value of investment in joint venture	12,776	13,879
Deferred intra-entity profit margin	5,495	5,456
Goodwill	(4,720)	(4,720)
Proportional share of equity investment in joint venture	$ 13,551	$ 14,615

Joint Venture - Summary of Fina

Joint Venture - Summary of Financial Information of Joint Ventures (Operations Data) (Details) - USD ($) $ in Thousands	3 Months Ended
	Sep. 30, 2022	Jun. 30, 2022	Sep. 30, 2021	Jun. 30, 2021
Schedule Of Equity Method Investments [Line Items]
Total net revenue	$ 96,493		$ 107,442
Gross Profit	34,597		39,524
Net loss	$ (5,449)		$ (1,028)
Joint venture
Schedule Of Equity Method Investments [Line Items]
Total net revenue		$ 26,740		$ 7,669
Gross Profit		4,596		2,340
Net loss		(752)		(693)
Net loss attributable to the Company		$ (368)		$ (340)

Joint Venture - Summary of Fi_2

Joint Venture - Summary of Financial Information of Joint Ventures (Balance Sheet Data) (Details) - USD ($) $ in Thousands	Sep. 30, 2022	Jun. 30, 2022	Sep. 30, 2021	Jun. 30, 2021
Schedule Of Equity Method Investments [Line Items]
Current assets	$ 335,265	$ 350,890
Total assets	466,349	472,849
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities	192,536	208,858
Stockholder's equity	46,991	53,189	$ 45,765	$ 68,840
Total liabilities and stockholders' equity	$ 466,349	472,849
Joint venture
Schedule Of Equity Method Investments [Line Items]
Current assets		72,241		31,759
Non current assets		19,701		22,763
Total assets		91,942		54,522
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities		63,006		24,445
Non current liabilities		862		1,300
Stockholder's equity		28,074		28,777
Total liabilities and stockholders' equity		$ 91,942		$ 54,522

Joint Venture - Schedule of Def

Joint Venture - Schedule of Deferred Intra Entity Profit Margin from Sales (Details) - USD ($) $ in Thousands	3 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Schedule of Equity Method Investments [Line Items]
Total change in deferred intra-entity profit margin from sales	$ 39	$ 1,738
Joint venture
Schedule of Equity Method Investments [Line Items]
Previously deferred intra-entity profit margin from sales - recognized	(2,348)	(215)
Intra-entity profit margin from sales - deferred	2,387	1,953
Total change in deferred intra-entity profit margin from sales	$ 39	$ 1,738

Income Tax - Additional Informa

Income Tax - Additional Information (Details) - USD ($) $ in Thousands	3 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Aug. 16, 2022
Income Taxes [Line Items]
Income tax expense	$ 341	$ 431
Corporate alternative minimum tax			15%
Excise tax			1%
Gross unrecognized tax benefits	19,800
Uncertain tax benefits that, if realized, would affect the effective tax rate	$ 19,600
Subsequent period within which no material changes in unrecognized tax benefits are expected	12 months
Foreign
Income Taxes [Line Items]
Income tax expense	$ 300	$ 400